AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update

Study limitation reported by the research below: “Level of evidence is assigned as '7' (expert consensus/guideline) by default for panel recommendation documents, but the AGO panel uses its own internal grading system which may differ.”